BPC-157 Rotator Cuff Trial: What Registry NCT07803250 Actually Says
TL;DR: NCT07803250, registered 3 Sep 2026, is a 20-patient placebo-controlled pilot of BPC-157 after rotator cuff repair; no results exist yet.
What Is the New BPC-157 Rotator Cuff Trial?
ClinicalTrials.gov registration NCT07803250 describes a randomised, double-blind, placebo-controlled pilot trial of BPC-157 in patients undergoing arthroscopic rotator cuff repair, with the University of Arkansas listed as lead sponsor. The record was registered on 3 September 2026.[1] Twenty participants are planned, randomised to BPC-157 or a saline placebo for a 90-day post-operative period, with MRI-based tendon-healing assessment at the centre of the design.[1]
It is the second placebo-controlled human BPC-157 trial we are tracking. The first, Hudson Biotech's hamstring-strain study (NCT07437547), began recruiting in February 2026 and is covered in our BPC-157 first controlled human trial guide.[2] The two registrations target different tissues, with different sponsors and very different sample sizes.
For a compound-level summary of the preclinical literature, see our BPC-157 research overview. Velox Peptides supplies BPC-157 as an HPLC-verified reagent for in vitro research only. View the product page →
How Is the Rotator Cuff Trial Designed?
Per the registry summary, the trial is small by design. A 20-patient pilot is typically intended to test feasibility and generate preliminary signal estimates rather than to deliver a definitive efficacy answer.[1] The registered assessments are:
Beyond MRI, the record lists patient-reported outcome measures, range of motion, and muscle strength measured by handheld dynamometry, together with blood biomarkers associated with collagen turnover and inflammation.[1] The inclusion of biomarkers is notable: mechanistic readouts in humans would be the first of their kind for BPC-157, whose proposed mechanisms rest almost entirely on rodent and cell-based work.
Lead sponsor: University of Arkansas. Randomised, double-blind, placebo-controlled pilot. Registered on ClinicalTrials.gov.
Why Does a Second BPC-157 Trial Matter for the Evidence Base?
Independent reporting has repeatedly described BPC-157's evidence base as a large rodent literature with scant controlled human data.[3] A 2025-26 exchange in the journal literature also questioned how concentrated that rodent work is within a small number of research groups; our BPC-157 evidence dispute guide summarises it.
Two independent registrations from different sponsors, in different tissues, would begin to address that concentration problem, because replication outside the original research groups is what the literature has lacked. In July 2026, FDA reviewers told the Pharmacy Compounding Advisory Committee that existing studies were too small and short to establish safety or effectiveness, and the committee still voted narrowly to recommend BPC-157 for the 503A Category 1 list.[4] Our PCAC July 2026 guide covers the hearing.
What Could the Results Mean for Researchers?
A pilot cannot be conclusive
With 20 participants, even a clear difference between arms would be a hypothesis for a larger trial rather than an established finding. Confidence intervals will be wide.
Null results are informative
Given how little controlled human data exists, a null or inconclusive pilot would itself be a useful data point for anyone assessing the translational evidence.
No results exist yet
As of 7 October 2026 the record is a few weeks old. No interim or topline data have been reported, and none should be assumed.
What Are the Limitations of This Registry Record?
Three caveats apply. First, a registration is a plan, not a result: enrolment, endpoints and timelines can change, and we reviewed the record only through registry summaries rather than a full protocol.[1] Second, a single surgical indication cannot be generalised to other tissues or uses. Third, the formulation, purity standard and regulatory pathway of a sponsor-run trial are not equivalent to any research-use peptide sold commercially, including Velox Peptides' own BPC-157.
None of this constitutes evidence of any safety, efficacy or health outcome in humans, and nothing here describes a property of Velox Peptides' research-grade BPC-157, which is supplied strictly for in vitro laboratory use.
Velox Peptides Supply Information
BPC-157 is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- University of Arkansas. BPC-157 and tendon healing after arthroscopic rotator cuff repair (randomised, double-blind, placebo-controlled pilot). ClinicalTrials.gov registration NCT07803250, registered 3 September 2026. clinicaltrials.gov/study/NCT07803250.
- Hudson Biotech. BPC 157 for Acute Hamstring Muscle Strain Repair. ClinicalTrials.gov registration NCT07437547. clinicaltrials.gov/study/NCT07437547.
- STAT News. BPC-157: The peptide with big claims and scant evidence. Published 3 February 2026. statnews.com.
- FDA Pharmacy Compounding Advisory Committee. 503A Category 1 review of BPC-157, KPV, TB-500, MOTS-c, Semax, DSIP and Epitalon. Meeting 23–24 July 2026. See our PCAC July 2026 guide.
Frequently Asked Questions
What is the new BPC-157 rotator cuff trial?
NCT07803250 is a randomised, double-blind, placebo-controlled pilot trial registered on ClinicalTrials.gov on 3 September 2026, with the University of Arkansas as lead sponsor. It plans to enrol 20 patients undergoing arthroscopic rotator cuff repair and compare BPC-157 against a saline placebo over a 90-day post-operative period.
What will the rotator cuff trial measure?
The registration lists tendon healing assessed by postoperative MRI, patient-reported outcome measures, range of motion, and muscle strength by handheld dynamometry, plus blood biomarkers associated with collagen turnover and inflammation.
Is this the first controlled human trial of BPC-157?
No. Hudson Biotech's Phase 2 hamstring-strain trial (NCT07437547) has been recruiting since February 2026 and was registered first. NCT07803250 is a second, separate placebo-controlled registration, in a different tissue and a much smaller sample.
Are there any results from NCT07803250?
No. As of 7 October 2026 the trial is newly registered and no interim or topline data have been reported. Nothing in this guide describes a human outcome.
Does the trial tell us anything about research-grade BPC-157?
No. A sponsor-run clinical trial uses its own formulation, purity standard and regulatory pathway. Velox Peptides' BPC-157 is a laboratory reagent for in vitro use only and is not the material used in any clinical trial.